Sionna Therapeutics (SION) Fundamental Analysis: Revenue, Earnings & Valuation

7.13 / 10

Outperform

Fundamental analysis rates SION as Outperform with a 7.13 score. Strengths include high inventory turnover, accounts receivable efficiency, solid interest coverage, and favorable asset‑MV and revenue‑MV differentials. Weak points are low fixed‑asset turnover and a high income‑tax‑to‑profit ratio.

Analysis Checks(8/10)

Revenue-MV

Value-0.08

Score3/3

Weight30.61%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight1.63%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-1.74%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-1.72%

1M Return-0.65%

PB-ROE

Value4.51

Score2/3

Weight34.32%

1M Return8.98%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-3.91%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-3.23%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-1.94%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-1.91%

1M Return-0.74%

Asset-MV

Value-0.55

Score3/3

Weight47.89%

1M Return13.09%

Is SION undervalued or overvalued?

SION scores 7.13/10 on fundamentals and holds a Discounted valuation at present. Backed by its -31.79% ROE, 0.00% net margin, -22.17 P/E ratio, 5.44 P/B ratio, and 88.24% earnings growth, these metrics solidify its Outperform investment rating.